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Abstract. We have recently described a novel cDNA,
SR13 (Welcher, A . A., U. Suter, M . De Leon, G. J.
Snipes, and E. M. Shooter. 1991. Proc. Natl. Acad.
Sci. USA. 88 .7195-7199), that is repressed after sciatic
nerve crush injury and shows homology to both the
growth arrest-specific mRNA, gas3 (Manfioletti, G.,
M. E. Ruaro, G. Del Sal, L. Philipson, and
C. Schneider. 1990. Mol. Cell Biol. 10:2924-2930),
and to the myelin protein, PASII (Kitamura, K., M.
Suzuki, and K. Uyemura. 1976. Biochim. Biophys.
Acta. 455 :806-816). In this report, we show that the
22-kD SR13 protein is expressed in the compact portion
of essentially all myelinated fibers in the peripheral
nervous system. Although SR13 mRNA was found in
the central nervous system, no corresponding SR13
YELIN is a highly specialized extension of the plasma
membrane of Schwann cells in the peripheral ner- M vous system (PNS)' and of oligodendrocytes in
the central nervous system (CNS). Its characteristic mul-
tilaminated structure is produced by the wrapping of the
plasma membrane of myelin-forming cells around axons,
forming a cylindrical sheath which is divided longitudinally
into discontinuous segments, interrupted by the nodes of
Ranvier (for a detailed description see Peters et al ., 1976).
When viewed in cross section, myelin is composed of alter-
nating apposing cytoplasmic and extracellular surfaces of
the plasma membrane which give rise to the major dense
line and the intraperiod line, respectively (Napolitano and
Scallen, 1969). This highly ordered membranous sheath
facilitates the electrical conduction velocity of myelinated
axons (Ritchie, 1984).
Peripheral and central nervous system myelin have been
extensively studied and, although their general organization
is quite similar, they differ with regards to morphological ap-
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protein could be detected by either immunoblot analysis
or by immunohistochemistry. Northern and immunoblot
analysis of SRI 3 mRNA and protein expression during
development of the peripheral nervous system reveal a
pattern similar to other myelin proteins. Furthermore,
we demonstrate by in situ mRNA hybridization on tis-
sue sections and on individual nerve fibers that SR13
mRNA is produced predominantly by Schwann cells.
We conclude that the SR13 protein is apparently exclu-
sively expressed in the peripheral nervous system
where it is a major component of myelin. Thus, we
propose the name Peripheral Myelin Protein-22 (PMP-
22) for the proteins and cDNAs previously designated
PASII, SR13, and gas3.
pearance and protein composition (Morell et al., 1989). In
the CNS, each oligodendrocyte produces up to 30 internodal
myelin segments which tend to have fewer lamellae than
PNS myelin . As opposed to the oligodendrocyte, a single
Schwann cell can produce only one internodal myelin seg-
ment around a single axon in the PNS. Additional morpho-
logical differences between central and peripheral myelin
have been described (Peters et al., 1976) .
The major structural myelin proteins in the CNS include
proteolipid protein (PLP), the myelin basic proteins (MBP),
and myelin-associated glycoprotein (MAG) (for review see
Campagnoni, 1988). PLP is a highly hydrophobic trans-
membrane protein which projects into both the major dense
line, and the intraperiod line, and has been implicated in
maintaining the apposition between the extracellular faces
(the intraperiod line) of myelin (Hudson et al ., 1987). In
contrast, MBP is a highly charged soluble intracellular pro-
tein whose expression is limited to the major dense line.
MAG is a glycoprotein that is structurally related to the im-
munoglobulin gene superfamily (Salzer et al., 1987). This
protein has been hypothesized to play a role in myelin-axon
interactions because of its homology to molecules involved
in cellular recognition and adhesion and its immunolocaliza-
tion to the axoplasmic surface of myelin, although this local-
ization is controversial (Trapp and Quarles, 1984). Recent
experiments examining recombinant retrovirus-mediated
225MAG overexpression in mixed Schwann cell neuron cultures
also provide support for the hypothesis that MAG is involved
in axon-Schwann cell interactions (Owens et al., 1990).
Protein zero (PO), MBP, and MAG are the major protein
components of PNS myelin (reviewed in Morell et al ., 1989;
Lemke, 1988) . P0, a transmembrane glycoprotein which,
like MAG, belongs to the immunoglobulin gene superfamily
(Lai et al., 1987; Lemke et al ., 1988) is the most abundant
protein in PNS myelin. The immunoglobulin-like extracellu-
lar domain of PO is located in the intraperiod line and has
ledto the hypothesis that PO may be responsible for the adhe-
sion between the extracellular surfaces of the myelin plasma
membrane. Recent studies on cultured cells clearly demon-
strate the capacity of PO to undergo homophilic interactions
(Filbin et al., 1990; Schneider-Schaulies et al ., 1990;
D'Urso et al., 1990).
The regulation of myelin protein expression is under ex-
quisite control because of the highly specialized function of
myelin in the nervous system. In development and after in-
jury to the PNS, cessation of Schwann cell proliferation is
followed by myelin formation (Asbury, 1967) . The synthesis
of the major myelin proteins correlates closely with the for-
mation of myelin during the development of both the CNS
and PNS (Uyemura et al ., 1979 ; Lamperth et al ., 1990;
Kronquist et al., 1987; Stahl et al ., 1990). After peripheral
nerve injury, myelin protein expression is quickly dimin-
ished, presumably because of transcriptional regulation ini-
tiated by loss of axonal contact. Myelin protein synthesis re-
sumes in crush-lesioned peripheral nerves with a time
course comparable to the remyelination of regenerating
axons (Trapp et al., 1988 ; LeBlanc and Poduslo, 1990;
Mitchell et al., 1990). Thus, myelin protein expression
shows a similar pattern of regulation both during develop-
ment and during nerve regeneration.
Recently, we described the cloning and initial character-
ization of a putative myelin protein, designated SRI3, which
was isolated by differential screening of cDNA libraries from
injured versus uninjured rat sciatic nerves (Welcher et al.,
1991b) . The SR13 cDNA sequence predicts a 160-amino
acid protein of 18 kD. Nucleotide sequence comparisons
revealed an extensive homology of SR13 with the growth-
arrest specific gene gas3 (Manfioletti et al., 1990) and con-
siderable amino acid identity with the partial amino acid se-
quence of PAS-II, a protein previously isolated from bovine
peripheral myelin (Kitamura et al., 1976). Based on these
findings and preliminary immunohistochemical studies, we
suggested that SR13 is a myelin protein (Welcher et al .,
1991b) . Furthermore, since gas3 has been proposed as a
regulator ofcell growth in tissue culture fibroblasts, we have
been interested in examining the possibility of a similar
regulatory function for SR13 in vivo. Because ofthe associa-
tion of SR13/gas3 with growth arrest, it was also of interest
to examine the expression of SRI3 during periods of cell di-
vision in development and after nerve injury.
We have characterized the time course of SRI3 expression
and its anatomical localization during myelination as well as
after nerve injury. In these studies, we have demonstrated
that SR13 is a 22-kD myelin protein which is expressed ex-
clusively in the PNS. Thus, we propose the name Peripheral
Myelin Protein 22 (PMP-22) for this protein that was previ-
ously designated SRI3, gas3, and PAS-II.
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Materials andMethods
Animal Care and Surgery
All surgical procedures followed the National Institutes of Health (NIH)
guidelines for the care and use of laboratory animals at Stanford University.
Male Sprague-Dawley rats (6-wk old; Bantin and Kingman, Inc., Fremont,
CA) were anesthetized by intraperitoneal injection ofa mixture ofketamine
and chloral hydrate. The right sciatic nerves were exposed and crushed for
30 s with No. 5 jeweler's forceps -2-mmdistal to the hip joint. In a similar
fashion, the contralateral nerve was exposed but not crushed. At timed in-
tervals, the crush-lesioned animals and developing rat pups wereeuthanized
in a C02 atmosphere. Sciatic nerves, brains, and spinal cords were quickly
removed and snap frozenon dry iceor placed immediately into 4% parafor-
maldehyde in 0.1 M sodium phosphate, pH 7.4, for paraffin embedding or
in isotonic glutaraldehyde buffer (0.33 M sodium cacodylate, 2 .7
glutaraldehyde, pH 7.4) followed by postfixation in aqueous 2% osmium
tetroxide before embedding in LX112 resin. Selected tissue blocks were
processed for EM.
Preparation ofAnti-PMP 22Antibodies
Two peptides were selected using hydrophilicity and surface probability
predictions based on the primary amino acid sequence of PMP-22/SR13.
Peptide 1
￿
27GlnTrp-LeuVal-Gly-Asn-Gly-His-ArgThr-Asp-LeuTrp-
Gln-Asn-Cys°2-000H
Peptide 2
￿
117Tyr-Thr-Val-Arg-His-Ser-GluTrp-HisVal-Asn-Asn-Asp-
Tyr-Ser-Tyrl33-Cys-000H
(A carboxy-terminal cysteine wasadded for cross-linking purposes) . Amino
acid numbering refersto the primary amino acid sequenceof PMP-22/SR13
(Welcher et al., 1991b). Both peptides were synthesized on an automated
peptide synthesizer (Milligen/Biosearch, Burlington, MA) and cross-linked
to keyhole limpet hemocyanin (Calbiochem-Behring Corp., San Diego,
CA) as follows: 250 pl keyhole limpet hemocyanin (20 mg/ml in 50 mM
sodium phosphate, pH 6) was mixed with 25 lal m-maleimidobenzoyl-
N-hydroxysuccinimide ester (Calbiochem-Behring Corp.; 100 mg/ml in
tetrahydrofuran). 250 pl 50 mM sodium phosphate, pH 6, was added and
the mixture was incubated for30 min at roomtemperature with gentle agita-
tion. 1-ml peptide solution (5 mg/ml in 50 mM sodium phosphate, pH 6)
was added and the mixture was incubated with rocking for another 3 h at
room temperature. The cross-linked proteins were then dialyzed against
PBS for 48 h at 4°C with several buffer changes. Insoluble material was re-
moved by centrifugation and the volume adjusted to 2 ml with PBS. 250
pl ofthe conjugate was combined with 350 pl free peptide solution (3 mg/ml
in PBS) and 600 pd Freund's complete adjuvants (Sigma Chemical Co., St.
Louis, MO) was added. This cocktail was used for primary immunization
of female New Zealand rabbits. The rabbits were boosted 14, 38, and 58 d
after the initial immunization with the same solution except that Freund's
incomplete adjuvant was used. Both peptides gave rise to comparable an-
tisera in two different rabbits as judged from solid-phase ELISA.
Isolation ofProteins and ImmunoblotAnalysis
20 to 150 mg offrozen tissue was added to 1 ml of a PBS-1% SDS solution.
The tissue was disrupted using a polytron (Brinkmann Instruments, Inc.,
Westbury, NY) at the highest setting for 10 s, after which the sample was
placed in a 100°C water bath, and boiled for 3 min. Insoluble material was
pelleted by centrifugation at 5,000 rpm for 5 min at room temperature in
a low speed centrifuge (Beckman Instruments, Inc., Fullerton, CA). The
supernatant was removed to a microfuge tube and centrifuged at 10,000 rpm
for 10 min at room temperature. Dilutions of the supernatants were used
to determine the protein concentration by the BCA protein assay system
(Pierce Chemical Co., Rockford, IL) using the manufacturer's reagents and
instructions.
Equivalent amounts of the protein samples were added to sample buffer
containing 0.5% 2-mercaptoethanol, electrophoresed through 12 .5
SDS-polyacrylamide gels, and transferred to nitrocellulose as described
previously (Welcher et al., 1991x). The filters were blocked with a solution
of PBS-0.05% Tween-5% nonfat milk (Blotto), incubated with antiserum
to peptide 1 diluted 1:1,000 in Blotto, followed by incubation with affinity
purified 12sí-protein A (Amersham Corp., Arlington Heights, IL; 45
226Figure 1 . Anti-PMP22 peptide antisera
recognize a 22-kD protein from rat sci-
atic nerve. Proteins (50 ug per lane)
from adult rat sciatic nerves were elec-
trophoresed through a SDS-polyacryl-
amide gel, transferred to nitrocellulose,
and the membrane was cut in half. One
half (lane 1) was incubated with pre-
blocked (30 min, 1 mg/ml peptide 2)
anti-peptide 2 antisera (final concentra-
tion 1:1,000) . The other half(lane 2) was
incubated with anti-peptide 2 antisera only (1:1,000) . Bound anti-
body was detected with ' 21I-Protein A followed by autoradiog-
raphy. Position of the molecular weight standards is indicated on
the right .
mCi/mg) at a concentration of 2 itCi/10 ml of Blotto solution . All incuba-
tions were at room temperature for 1 h each . The filters were autoradi-
ographed, and films scanned as described for the Northern blots .
Immunohistochemistry
Immunohistochemistry for the PMP-22 protein on 4% paraformaldehyde-
fixed paraffin-embedded tissue was performed as previously described
(Welcher et al ., 199lb) except that both primary antipeptide antibodies were
used simultaneously at a dilution of 1:100 and the blocking and primary an-
tiserum solutions contained 0.1% Triton X-100 (Sigma Chemical Co .) . Rab-
bit anti-humanMBP serum (DAKOPATTS, Copenhagen) was used at a di-
lution of 1:60. For high resolution light microscopic and immunoperoxidase
studies, nerves were embedded in LX 112 (Ladd Research Industries, Inc.,
Burlington, VT) and 0.5-i4m-thick sections were cut on an ultramicrotome
(Reichert Jung, Vienna) and either stained with 1 % toluidine blue oretched
with sodium hydroxide-saturated ethanol for 20 s as described by Baskin
et al . (1979) and processed for immunohistochemistry as described above .
RNA Isolation andNorthern Blots
Total RNA was extracted from at least six pooled sciatic nerves according
to the method ofChomczynski and Sacchi (1987) and analyzed by Northern
blotting using Hybond-N membranes (Amersham Corp.) . Total RNA was
quantitated initially by optical density measurements at260 run and verified
by ethidium bromide staining . Blots were probed with a 32p-labeled PMP-
22/SR13 cDNA probe (hexanucleotide labeling kit ; Boehringer Mannheim
Corp., Indianapolis, IN), washed under high stringency conditions, and ex-
posed to XAR5 films (Eastern Kodak Co ., Rochester, NY) . Quantitative
analysis was performed by densitometric scanning of appropriate (linear
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rangeexposed) autoradiograms using a laser densitomer (LKB Instruments,
Gaithersburg, MD) .
In Situ mRNA Hybridization
The 1.6-kb Xbal fragment of the PMP-22/SR13 cDNA was subcloned in
both orientations into the Xbal site of the pSP72 (Promega Biotec, Madi-
son, WI) plasmid . Sense and antisense riboprobes, containing 35S CTP
(Amersham Corp .), were synthesized according to the manufacturer's in-
structions. Paraffin sections cut onto 3-aminopropyltriethoxysilane-treated
glass slides (Rentrap et al ., 1986) were deparaffinized in xylenes, re-
hydrated through graded ethanol solutions, and treated sequentially with
4% paraformaldehyde (5 min), 20 mM HCl (3 min), 0.01% Triton X-100
(3 min), 1 ug/mI proteinase K (10 min ; 50mM Tris, 3 mM EDTA, pH 8 .0),
and 4% paraformaldehyde (5 min) each separated by two washes in PBS
(3 min each ; supplemented with 0 .2 % glycine after theproteinase K incuba-
tion) . The sections were then dehydrated through graded ethanol solutions
and air dried . For nerve tease experiments, normal sciatic nerves were fixed
in buffered formalin, teased onto silane-treated slides, and dried in a 37°C
oven for 3 h . The teased nerves were treated as described above, starting
with the4% paraformaldehyde solution . Sections were prehybridized with
25 mM Tris, 0.75 M NaCl, 25 mM EDTA, IX Denhardt's solution, 50%
formamide, 0.2% SDS, 225 kg/ml sheared salmon sperm DNA, 225 lag/ml
poly A, 15 mM DTT at 42°C for 3 h and hybridized for 16 h at 53°C in
prehybridization solution containing 106 cpm sense or antisense probes
and 5 % dextran sulfate . Hybridization signals were detected with 0-max
high resolution film (Amersham Corp .) or withphotographicemulsion. For
double label experiments, the sections were first hybridized with the PMP-
22 sense and antisense probes then inununolabeled with rabbit anti-bovine
S-100 (1:100, Dako Corp ., Santa Barbara, CA) using the hybridization and
peroxidase antiperoxidase techniques described above .
Results
PMR22, a 22-kDProtein, Is a Componentofall
Myelin Sheaths in the Peripheral NervousSystem
Synthetic peptides corresponding to the two predicted major
hydrophilic regions of the PMP-22 molecule were con-
jugated to keyhole limpet hemocyanin and used to immunize
rabbits . The antisera to both peptides were found to be
specific for a 22-kD protein on electrophoretic transfers (im-
munoblots) of total protein isolated from rat sciatic nerves .
Fig . 1 shows that the anti-PMP-22 peptide 1 antiserum
specifically recognizes a 22-kD protein in sciatic nerves
Figure 2. Immunoperoxidase detection ofthe PMP-22 protein in 0.5-Am cross sections of normal rat sciatic nerve using pooled antipeptide
antibodies (a) or preimmune sera (b), both diluted 1:50. Sciatic nerve from 30-d-old rats was fixed with isotonic glutaraldehyde and embed-
ded inLX 112 . For immunohistochemistry, 0.5 um sections were etched with ethanolic sodium hydroxide for 20 s before immunoperoxidase
staining by the peroxidase-antiperoxidase method . Toluidine blue stain highlights myelin in adjacent plastic sections (c) . Bar, 20 pm .(Fig. 1, lane 2) which is abolished by preincubating the an-
tiserum with PMP-22 peptide 1 (Fig . 1, lane 1) . ThePMP-22
protein is predicted to have a molecular mass of 18,000 based
on the peptide sequence and contains a consensus sequence
for N-linked glycosylation (Welcher et al ., 1991b) which
predicts a total molecular mass consistent with a 21-22-kD
protein . Both antipeptide antisera had identical specificities
on immunoblots and in immunohistochemical studies . Con-
trol blots using preimmune serum were consistently negative
(data not shown) .
While PMP-22 is expressed at high levels in normal adult
rat sciatic nerves, Northern blot analysis showed that PMP-
22 mRNA expression was undetectable in liver and kidney
but was present in trace levels in heart and skeletal mus-
cle (Welcher et al ., 1991b) . Immunoblot and immunohisto-
chemical analysis of the PMP-22 protein agreed with the
previous results and identified no detectablePMP-22 protein
expression in a variety of tissues including heart, gut, lung,
adrenal gland, kidneys, skeletal muscle, thymus, and spleen
except in the myelin of the innervating nerves (data not
shown) . Initial immunohistochemical results had demon-
strated that PMP-22 was associated with the myelin sheaths
of axons in the sciatic nerve (Welcher et al ., 1991b) . This
finding was confirmed by immunoperoxidase studies on
0.5-,urn plastic sections which localized the PMP-22 protein
to the compact portion of the myelin sheaths of essentially
all myelinated axons in the sciatic nerve (Fig . 2 a) when com-
pared to toluidine blue-stainedadjacentplastic sections (Fig .
2 c) . It was concluded that PMP-22 protein expression is ap-
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Figure3 Developmental expression ofPMP-22 mRNA and protein
in the sciatic nerve. (A) RNA was isolated from rat sciatic nerves,
fractionated by formaldehyde-agarose gel electrophoresis (5 Fig to-
tal RNA per lane), transferred to a nylon membrane, hybridized
with a 32P-labeled PMP22 probe, and autoradiographed . The ages
of the rats (in days) are indicated above the lanes . mRNA size was
determined using RNA molecular weight standards . (B) Proteins
were isolated from rat sciatic nerves, fractionated by SDS-poly-
acrylamide electrophoresis (50 Fig of protein per lane), and trans-
ferred to nitrocellulose . The membrane was incubated consecu-
tively with antisera 2 (1:1,000), 1251-Protein A, and visualized by
autoradiography . The ages of the rats (in days) are indicated above
the lanes. SN refers to proteins (1 lAg, left side ; 50 Fig, right side)
isolated from 60-d-old rats . Position of the protein molecular
weight standards is indicated on the left . (C) Quantitation ofPMP
22 mRNA and protein expression . Autoradiographs were scanned
and the expression plotted relative to the expression at 60 days
(100%) . (a) RNA expression ; (e) protein expression .
patently restricted to the nervous system where it is as-
sociated with myelin sheaths .
PMR22 Expression Correlates with Myelin Formation
during SciaticNerve Development
After having identified PMP-22 as a putative myelin protein,
it was important to compare its expression with other myelin
proteins to establish the role ofPMP-22 in myelin formation
and to investigate its role in cellular growth arrest . Thus, a
time course study of PMP-22 expression was undertaken
during the immediate postnatal period to adulthood, the time
interval in which Schwann cell proliferation ceases and my-
elination ensues in the rat sciatic nerve (Friede and Samoraj-
ski, 1968) . Northern blot analysis of total RNA isolated
from sciatic nerves at different time points in development
showed that a single 1.8-kb PMP-22 mRNA species is ini-
tially expressed at low levels in the immediate postnatal
period (10% ofmaximal) but is rapidly induced to adult lev-
els over the first three postnatal weeks (Fig . 3 A) . Densito-
metric analysis of theRNA blots demonstrated that PMP-22
mRNA expression reached half-maximal adult levels be-
tween postnatal days two to seven and increased to near max-
imal levels by postnatal day 21 (Fig. 3 C) .
Parallel immunoblot analysis of PMP-22 protein expres-
sion in the developing rat sciatic nerve revealed that, as ex-
pected, the production of PMP-22 protein lags temporally
behind PMP-22 mRNA expression (Fig . 3 B) . Overall, how-
ever, protein and mRNA display parallel expression pat-
228Figure 4 . Developmental expression of PMP-22 in the rat sciatic nerve . Sciatic nerves were collected from 0, 3, 7, 14, 21, and 200-d-old
rats and fixed by immersion in 4% paraformaldehyde in PBS and processed for paraffin embedding. 5-gm paraffin sections were cut and
processed forPMP-22 (1:100 each)andMBP (1:60) immunohistochemistry as described in Materials and Methods . Control sections were
reacted with the corresponding preimmune sera (1:100 each) . Toluidine blue-stained 0.5-Am plastic sections from each nerve sample are
shown at the right for comparison . Bar, 25 Am .
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229Figure S. Developmental expression of PMP22 mRNA and protein in brain and spinal cord preparations . (A) RNA was isolated from
the brain or spinal cord, fractionated by formaldehyde-agarose gel electrophoresis (5 jig total RNA per lane), and analyzed as described
in Fig 3. The left panel showsmRNA from the brain ; the ages ofthe rats (in days) are indicated above the lanes . mRNA size was determined
using RNA molecular weight standards . (Right) Relative expression ofPMP22 mRNA in brain (B), spinal cord preparation (SCP), and
sciatic nerve (SN) in 5 wg of total RNA per lane . (B) Proteins were isolated from the brain or spinal cord, and analyzed as described
in Fig 3. The ages of the rats (in days) are indicated above the lanes. SN refers to proteins (1 jig, left side ; 50 lcg, right side) isolated from
60-d-old rats . Brain samples (Fd9-200) contained 100 hg of protein . Spinal cord preparation samples (SCP, 14-200) contained 50 Wg of
protein. Positions of the protein molecular weight standards are indicated on the left .
terns . PMP-22 protein levels are below detectable limits
in the immediate postnatal period but reach half-maximal
values between postnatal days 10 and 15 and maximal levels
by postnatal day 21 (Fig . 3 C) . Immunohistochemical analy-
sis showed that PMP-22 protein expression is restricted to
myelin and correlates temporally with the formation of my-
elin when compared to the expression of MBP, another
component of compact myelin, and to myelin formation as
monitored using toluidine blue-stained plastic sections of
developing rat sciatic nerves (Fig . 4) .
Expression ofPMR22 Is DramaticallyLower in
the Central Nervous System than in the Peripheral
Nervous System
Previous studies indicated thatPMP22 mRNA is present in
low levels in the brain, (Welcher et al ., 1991b) . Thus, it was
of interest to determine ifPMP22 was also a component of
myelin in the CNS . Initial attempts to visualize PMP-22 pro-
tein in the brain using immunohistochemical methods were
unsuccessful, a finding which was subsequently explained by
Northern and immunoblot analysis . Quantitation of North-
ern blots of total RNA isolated from the brain revealed that
the mRNA for PMP22 is -300-fold less abundant in brain
than in sciatic nerve (Fig . 5 A, lanes B versus SN) . Fur-
thermore, in contrast toPMP-22mRNAexpression in periph-
eral nerve, the brainPMP22 mRNA levels are not develop-
mentally regulated (Fig. 5 A, lanes E19-200) . No PMP22
protein was detectable in 100 hg of brain tissue at any time
point under experimental conditions that were able to de-
tect PMP-22 protein from 1 p,g of nerve tissue (Fig . 5 B) .
It is concluded that PMP-22 protein levels in the brain are
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at least 100-fold lower than in peripheral nerve . As a second
CNS tissue, spinal cord preparations (SCP) were examined
for PMP-22 expression . Initial quantitative Northern blot
analysis of SCP-derived RNA revealed appreciable levels of
PMP-22 mRNA expression (Fig . 5 A, lane SCP) . Similarly,
relatively high levels of PMP-22 protein were detected in
SCP by immunoblot analysis (Fig . 5 B) . In situ mRNA hy-
bridization (Fig . 6 a) and immunohistochemistry (Fig . 6 c),
however, clearly demonstrated the expression of PMP-22
protein and mRNA in the PNS-derived dorsal and ventral
spinal roots but failed to provide evidence of significant
PMP22 expression in the spinal cord . These results suggest
that some, if not most, of PMP-22 mRNA and protein de-
tected in theSCP is because ofPMP-22 expression in the spi-
nal roots of peripheral nerves . It remains possible that the
absolute levels of PMP-22 mRNA and protein in the spinal
cord differs from the low levels observed in the brain since
a direct comparison between these structures cannot be
made from these results . We conclude that, while PMP-22
mRNA may be expressed in the CNS at very low levels in
a nondevelopmentally regulated manner, PMP22 protein
and mRNA levels are expressed atmuch higher levels in the
PNS . Although we cannot exclude regional expression of
PMP22 in the brain, the protein is not a major component
of CNS myelin .
PMR22 Expression Correlates with Myelin
Degradationand Remyelination during Sciatic
Nerve Regeneration
PMP-22 was originally identified based on its precipitous
down regulation after sciatic nerve crush injury. We have
Figure 6. PMP 22 immunohistochemistry and in situmRNA hybridization on cross sections of the spinal cord . (a) PMP-22 immunoperoxi-
dase studies performed on cross sections of spinal cord demonstrate dark staining for PMP22 protein in the dorsal and ventral spinal
nerve roots, but no immunoreactivity is present within the spinal cord . (b) Control slides reacted with preimmune sera show no significant
immunoreactivity . These sections are lightly counterstained with hematoxylin . The pattern ofmRNA expression parallels the protein ex-
pression as demonstrated by in situ mRNA hybridization on adjacent sections of spinal cord probed with 'SS-labeled PMP-22 antisense
(c) and sense (d) RNA . c and d are negative images of the resulting autoradiogram (i .e ., the portion of the autoradiography film exposed
by the radioactive probe is white) . Bar, 500 tm .Snipes et al . PMP-22: A Novel Peripheral Myelin Protein
￿
231Figure 7 . Expression of PMP-
22 mRNA and protein during
sciatic nerve regeneration.
Protein and mRNA were iso-
latedfrom rat sciatic nerves at
various days after a crush in-
jury. Samples were analyzed
by blotting as described in
Fig 3. Autoradiographs were
scanned, and the expression
plotted relative to the expres-
sion inthe contralateral, unin-
jured sciatic nerves (100%).
(n) mRNA expression; (9)
Days (After Crush)
￿
protein expression.
now characterized in more detail the expression of PMP-22
after sciatic nerve crush to compare it to similar studies
which have been performed using other known myelin pro-
teins. Sciatic nerves were crushed several millimeters distal
to the hip joint and marked with a loosely tied silk suture.
At predetermined times after crush injury, 1-2-cm segments
of sciatic nerve distal to the site of crush injury along with
sham-operated contralateral nerves were harvested. Special
care was taken to avoid the immediate area around the site
of injury to eliminate the effects of local inflammation.
Northern blot analysis confirmed the previously described
rapid decline of PMP-22 mRNA to <10% of normal adult
levels by 3-7 d after crush injury. This decline in the levels
of PMP-22 mRNA is paralleled by a slower decline of the
22-kD PMP-22 protein expression which reaches similar
low levels during days 10 to 20 after crush injury. Although
PMP-22 mRNAand protein have started to approach normal
levels by 40 d after crush (Fig. 7), the expression of protein
lagged behind .
Morphological Studies on PMP-22afterSciatic
Nerve Injury
Although the morphologic events after peripheral nerve in-
jury have been well described (for a historical perspective
see Weller and Cervos-Navarro, 1977), we have performed
anatomic studies in parallel with the protein and mRNA de-
tection experiments. This strategy allowed us to more pre-
cisely correlate the morphological changes with the pattern
of expression of the PMP-22 protein in the particular nerve
segments used for biochemical and molecular analysis. Fig.
8 shows the results of the immunohistochemical study of
PMP-22 and MBP expression after nerve injury. On the first
day after crush injury, the only pathological alteration in the
nerve segment distal to the site of crush injury is a slight
loosening of the myelin sheath. At this time, PMP-22 im-
munoreactivity is more evident in the myelin sheaths distal
to the site of crush injury than in the proximal nerve seg-
ment. This is probably because of loss of myelin integrity
and consequent increased antibody penetration since a simi-
lar increase in immunoreactivity was noted in nerve fibers
undergoing spontaneous Wallerian degeneration in aged rats.
Three days after crush injury, neurofilament immunoreac-
tivity is greatly diminished (data not shown) as the axons de-
generate. At this time point, the PMP-22 mRNA level has
fallen to 10% ofprecrush levels as the myelin sheaths are dis-
rupted and are being digested by the Schwann cells as re-
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flected in the persistently elevated levels of immunostain-
ing for PMP-22 and MBP By 7 d after crushinjury, PMP22
and MBP are found increasingly in "digestion chambers of
Cajal " a structure composed of Schwann cell cytoplasm sur-
rounding degenerating myelin ovoids. In situ mRNA hybrid-
ization for PMP-22 mRNA at 14 d after crush injury illus-
trates the downregulation of PMP-22 mRNA in the portion
of the sciatic nerve distal to the injury site when compared
to the proximal portion (Fig. 9). Wallerian degeneration con-
tinues through the first 2 wk after injury as the absolute
PMP-22 protein levels and PMP-22 immunoreactivity de-
cline. In our system, axonal regeneration is evident 21 d after
crush injury as shown by the presence of thinly myelinated
axons in toluidine blue-stained plastic sections and electron
micrographs (not shown). As demonstrated on immuno-
blots, PMP-22 protein levels start to increase by 21 d after
crush injury. Axon regeneration continues through at least
40 d after crushinjury as demonstrated by the Bielschowski
silver stain for axons (data not shown) . By 40 d after crush,
the PMP-22 immunoreactivity is present predominantly in
the many newly formed myelin sheaths and occasionally in
residual "digestion chambers of Cajal." This finding corre-
lates well with the Northern and immunoblot results which
demonstrate increased levels of PMP-22 protein and mRNA
40 d after crush injury.
PMR22Is ProducedbySchwann Cells
Our initial characterization ofPMP-22 provided no evidence
for significant expression of the PMP-22 protein outside of
the PNS. In addition, there is compelling evidence that PMP-
22 is a myelin protein and, therefore, must be synthesized by
Schwann cells. Yet, after clarification of a sequencing error
in the mouse gas3 cDNA, it is clear that PMP-22 and gas3
share 98 % amino acid identity over the complete protein se-
quence (data not shown) . Thus, PMP-22 is the rat homo-
logue to the mouse gas3 cDNA which was isolated from
growth-arrested fibroblasts (Schneider et al., 1988; Manfio-
letti et al., 1990). Since fibroblasts are also a component of
the nerve sheath, it seemed possible that endoneurial fibro-
blasts could be the major source of PMP-22 expression. Two
experiments were carried out to identify the cells that are
mainly responsible for PMP-22 expression. First, we per-
formed in situ mRNA hybridization for PMP-22 on teased
nerve preparations, reasoning that if Schwann cells are syn-
thesizing PMP-22, a signal should be observed with a lon-
gitudinal periodicity corresponding to the length of the inter-
nodal segment. Such an anticipated periodicity is evident in
Fig. 10 c which shows PMP-22 mRNA localized to the
perinuclear cytoplasm of a Schwann cell from a single my-
elin internode. This result was confirmed using double label-
ing combining in situ hybridization for PMP-22 mRNA and
immunoperoxidase staining for S-100 protein, a specific
marker for Schwann cells in peripheral nerves (Stefansson et
al., 1982). In control experiments (not shown), the in situ
hybridization procedure selectively diminished the subse-
quentimmunostaining for the S-100protein in the cytoplasm
more than the nucleus, although specific staining of the
nuclei could clearly be seen. The double-labeling studies
demonstrated that S-100positive Schwann cells also produce
PMP-22 mRNA (Fig. 10 a). While all of the S-100 positive
cells appear to express PMP-22 mRNA, there is a small
232Figure 8. Expression ofPMP-22 protein andMBPdetected by immunohistochemistry in the distal portion of the rat sciatic nerve at various
stages of Wallerian degeneration . Both PMP22 andMBP can be detected in degenerating myelin sheaths and in myelin ovoids within
"digestion chambers of Cajal° in these longitudinal sections of the rat sciatic nerves taken at 1, 3, 7, 14, 21, and 40 d after sciatic nerve
crush . Control sections are reacted with PMP-22 preimmune(MBP nonimmune) rabbit sera as the primary antisera . All sections are lightly
counterstained with hematoxylin . Bar, 25 ,am .
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233Figure 9 In situ mRNA hybridization performed 14 d after crush injury demonstrates the marked downregulation of PMP-22 mRNA in
a longitudinal section of the sciatic nerve distal (d), but not proximal (p), to the site of crush injury (between arrowheads) . Antisense
(a) and sense (b) 3'S RNA probes were hybridized to crush-injured rat sciatic nerves and detected by autoradiography . As in Fig . 6, the
negative image of the autoradiogram is shown . Bar, 0.5 mm.
population of cells that are producing PMR22 but do not
stain for S-100. These PMP-22+/S-100- cells may represent
rare fibroblasts or Schwann cells whose nuclei are out of the
plane of section . In teased nerve preparations, occasionally
more t4an one nucleus was observed associated with a single
internodal myelin segment, but there was never more than
one cell per internode that hybridized with PMP-22 anti-
sense mRNA . Thus, we conclude that Schwann cells are
responsible for synthesizing most, if not all ofPMP-22 . We
cannot exclude, however, the possibility that there is a small
population of other cell types expressing PMP-22 .
Discussion
In this report,we have established that the recently described
PMP-22 gene product is a component ofperipheral myelin .
This conclusion is based, in part, on immunohistochemistry
and in situ mRNA hybridization studies which indicate that
PMR22 mRNA is produced predominantly by Schwann
cells and that the PMR22 protein is localized to the compact
portion of the myelin sheath . The assignment of PMP-22 as
a peripheral myelin protein is further supported by the
finding that the regulation ofPMP-22 expression during de-
velopment and after nerve injury is similar to that of other
myelin proteins .
The pattern ofPMP-22 expression in the PNS during de-
velopment is essentially identical to other proteins of PNS
myelin, such as PO and MBP (Stahl et al., 1990 ; Wiggins et
al ., 1975 ; Lees and Brostoff, 1984) . Comparative side by
side immunohistochemical localizations of PMP-22 and
MBP during development reveal identical patterns ofexpres-
sion and correlate well with the formation of peripheral my-
elin as demonstrated using toluidine blue-stained plastic
sections . Previous studies havealso shown that PO has a simi-
lar pattern of expression as MBP (and therefore PMP-22)
during the development of the PNS (Garbay et al ., 1989 ;
Stahl et al ., 1990) . In theCNS, however, PMP-22 expression
does not correlate with development and the formation of
CNS myelin . The lack of regulation ofPMP-22 expression
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in the CNS is in marked contrast to the upregulation of the
major CNS myelin protein, PLP, during CNS development .
Gardinier et al . (1986) have shown that PLP mRNA is pres-
ent in the CNS at 3 d after birth and reaches a broad peak
at 2 to 4 wk of age. This expression pattern correlates well
with the progression of rat CNS myelin formation . Thus,
during the myelination period in the rat CNS, PLP mRNA
increases from undetectable at birth to adult levels by 28-d
postpartum (Naismith et al., 1985), while PMR22 mRNA
levels are unchanged and PMR22 protein is undetectable .
Interestingly, PLPmRNA and protein have been detected in
the peripheral nervous system although the PLP protein ap-
parently is not incorporated into PNS myelin (Puckett et al .,
1987) . In the PNS, PLP mRNA levels are not regulated dur-
ing development and after nerve injury (Gupta et al., 1991),
analogous to that reported here for PMR22 mRNA in the
CNS .
The pattern of expression of PMR22 in the distal nerve
stump after unilateral sciatic nerve crush was also compara-
ble to the expression of other PNS myelin proteins . Trapp
et al . (1988) have shown that, like PMP-22 mRNA, the
mRNA encodingMBP and PO decreased 40-fold by 5 d after
crush injury. By 21 d after nerve injury, the MBP and PO
mRNA levels began to increase again although no morpho-
logically detectable regeneration was observed (Trapp et al .,
1988) . Similarly, we show in this study thatPMP-22 mRNA
and protein expression are rising at 21 d after crush, a time
at which we and others (Nichols et al ., 1968) were able to
observe axon sprouting . Trapp et al . (1988) also demon-
strated that PO immunoreactivity, like PMR22 and MBP
shown here, was localized to degenerating myelin ovoids at
21 d after crush injury. Interestingly, PO expression is not
completely repressed by loss of axonal contact as demon-
strated by long-term tissue culture studies which indicated
that small amounts of PO are expressed constitutively by ma-
ture Schwann cells (Poduslo and Windebank, 1985) . Given
its possible role in cellular growth arrest, it would be ofcon-
siderable interest to determinine if PMP-22 was constitu-
tively expressed in mature nonmyelinating Schwann cells .
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.Overall, our results suggest that the regulation of PMP-22 af-
ter nerve injury is similar to other peripheral myelin pro-
teins.
We have previously shown that PMP-22 (SR13) has se-
quence homology with two partial peptide sequences of
PASII, a glycoprotein isolated from PNS myelin prepara-
tions. Although the reported molecular weight of PASII
(13,000, more recently 19,000; Uyemura and Kitamura,
1991) is considerably different from PMP-22, the sequence
identity, data indicating that PASII and PMP-22 are glycopro-
teins (see below), and the fact that PASII and, now, PMP-22
have been shown to be PNS specific, indicate that PASII
and PMP-22 are very likely to be identical proteins . It is a
plausible explanation that the smaller observed molecular
weight of PASII may be due to proteolytic degradation. If
PASII and PMP-22 are indeed the same protein, it is of in-
terest that PASII (PMP-22) has been isolated from purified
myelin preparations and identified as one of four major PNS
myelin proteins (Uyemura et al., 1978) . Densitometric scan-
ning of Coomassie-stained SDS-polyacrylamide gels of hu-
man peripheral myelin proteins suggest that the levels of the
comigrating PMP-22 and P2 proteins may be up to 10-20%
that of PO (Uyemura and Kitamura, 1991). This notion is fur-
ther supported by the high abundance of PMP-22 cDNA
clones in a sciatic nerve library (De Leon et al., 1991) and
the relative ease of PMP-22 detection in immunoblots using
low quantities of sciatic nerve homogenates. We conclude
that PMP-22 is a major component of PNS myelin .
The assertion that PMP-22 is a major component of the
PNS myelin sheath raises the question why this protein has
not been widely recognized earlier. Although we cannot offer
a definitive answer, there are several features of PMP-22 that
may have obscured its detection. First, PMP-22 has an ap-
parent molecular weight of 22,000 and thus would be ex-
pected to comigrate with the high molecular weight MBP
(21 .5 kD) on SDS-polyacrylamide gels as suggested by Uye-
mura et al . (1979) and does comigrate with another periph-
eral myelin protein, P2 (Uyemura and Kitamura, 1991). Sec-
ondly, during two dimensional-PAGE analysis of PMP-22,
we noticed a tendency of PMP-22 to form aggregates in the
absence of SDS which could possibly be attributed to the
highly hydrophobic nature of the PMP-22 protein (data not
shown) . Similar unusual biochemical characteristics are de-
scribed for other myelin proteins (e.g., PLP; see Agrawal
and Hartman, 1980) .
Comparison of the details of PMP-22 mRNA and protein
localization with other proteins expressed by Schwann cells
provides additional insight into the probable localization of
PMP-22 within the myelin sheath. First, the perinuclear in
situ mRNA localization of PMP-22 in the nerve tease prepa-
ration and on tissue sections is consistent with the hypothesis
that PMP-22 is an integral membrane protein. Two patterns
of mRNA localization for other myelin proteins have been
described; namely, a perinuclear localization exemplified by
PO and PLP mRNAs and a diffuse cytoplasmic localization,
often prominent in the paranodal regions of the Schwann
cell, as demonstrated for MBP mRNA (Trapp et al., 1987;
Griffiths et al ., 1989). These patterns of mRNA expression
are thought to reflect the fact that PO and PLP are integral
membrane proteins and must undergo intracellular process-
ing through the RER and Golgi apparatus as opposed to the
soluble MBPs which are presumably synthesized on free
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ribosomes (Trapp et al ., 1987). In support ofthis hypothesis,
Lamperth et al . (1990) have provided a direct demonstration
of PO mRNA processing using mRNA hybridization at the
ultrastructural level to show that PO mRNA is localized to
the RER. Secondly, we noticed by immunohistochemistry
that PMP-22 was not highly expressed in the Schwann cell
cytoplasm and was excluded from the cytoplasmic invagina-
tions into the myelin sheath known as Schmidt-Lanterman
incisures. Such a pattern of expression is reciprocal to that
ofproteins like S-100, which is found in the Schwann cell nu-
cleus, cytoplasm (Stefansson et al ., 1982), and Schmidt-
Lanterman incisures (unpublished observations) . Additional
evidence that PMP-22 is an integral membrane protein is
provided by analysis of the PMPR22 amino acid sequence
which reveals four hydrophobic stretches that may function
as transmembrane spanning regions as well as a consensus
site for N-linked glycosylation. gas3 mRNA (PMP-22)
translated in vitro in the presence of microsomes has been
shown to produce a endoglycosidase H-sensitive, proteinase
K-insensitive protein (Manfioletti et al., 1990). Taken to-
gether, these studies suggest that PMP-22 is a transmem-
brane glycoprotein expressed in PNS myelin and, as such,
probably has domains which project into both the major
dense line and the intraperiod line of myelin.
The protein composition of CNS and PNS myelin are
significantly different. There is, however, a pervasive notion
in the literature that both myelin structures are sufficiently
similar that two sets of analogous proteins serving similar
functions must existin both systems. According to this para-
digm, PO has been proposed to be the PNS homologue of
PLP. This hypothesis was basedon the fact that both proteins
are relativelyabundant, have similar molecular masses (PLP
= 30,000, Lemke, 1988; PO = 28,000, Sakamoto et al.,
1987) and display reciprocal patterns of expression in PNS
and CNS. In addition, the glycoprotein PO is a member of
the immunoglobulin gene superfamily of cell surface recep-
tors (Lemke and Axel, 1985) and has been proposed to bind
apposing membranes of the myelin sheath intraperiod line
(contiguous with the extracellular space) through homo-
philic mechanisms (Lemke, 1988). PLP may have a similar
function in the CNS as suggested by studies of thejimpy mu-
tation, a point mutation of a splice acceptor site in the PLP
gene (Hudson et al ., 1987) which causes specific intraperiod
line abnormalities in affected mice. Structurally, however,
PLP and PO are quite dissimilar. PLP contains four highly
hydrophobic regions and has been proposed to have up to
four membrane-spanning regions (Popot et al., 1991) . P0, on
the other hand, has a relatively hydrophobic, but glycosyl-
ated, extracellular domain, a single transmembrane domain,
and a very basic cytoplasmic domain (Sakamoto et al., 1987;
Lemke and Axel, 1985). As shown here, PMP-22 also dis-
plays a reciprocal pattern of expression compared to PLP
and, like PLP, has four hydrophobic domains which may
serve as membrane-spanning regions. Thus, we propose that
PMP-22 may serve, at least in part, as the PNS analogue of
PLP.
It was one ofthe goals ofthis study to examine the correla-
tion of PMP-22 expression with Schwann cell proliferation
because of the hypothesized role ofgas3 (PMP-22) in cellu-
lar growth arrest. gas3 mRNA is induced in quiescent
(growth-arrested) fibroblasts and is repressed in proliferating
cells (Schneider et al., 1988; Ciccarelli et al ., 1990). Our
236studies reveal no relationship between PMP-22 expression in
the CNS and the oligodendrocyte proliferation which occurs
postnatally in the rat. In the PNS, however, PMP-22 expres-
sion correlates inversely with Schwann cell division during
development. The situation after nerve injury is less clear.
Pelligrino and Spencer (1985) examined Schwann cell
proliferation after nerve injury using [3H]thymidine uptake
visualized by autoradiography. Two peaks of Schwann cell
proliferation were identified. The first peak appeared at N5 d
after injury and the second coincided with axon-glial contact
(Pellegrino et al ., 1982). Trapp et al. (1988) also noted that
the density of Schwann cells in the distal nerve stump after
nerve injury increased between 5-20 d. Our results demon-
strate that PMP-22 mRNA expression is minimal 5 d after
nerve injury and starts to increase by -20 d after crush in-
jury. The decrease in PMP-22 protein levellags significantly
behind the mRNA such that there is still a significant amount
of PMP-22 protein detectable by immunoblotduring the first
10 d after nerve injury. Our immunohistochemistry results
indicate that most ofthe PMP-22 protein observed during the
second week after nervecrushinjury is localized to degener-
ating myelin ovoids where it may be unavailable to serve a
regulatory function. These results can be interpreted in sev-
eral ways : First, PMP-22 (gas3) expression may not be
directly related to in vivo growth regulation and may reflect
irrelevant gene transcription in tissue culture. Indeed, there
is no direct evidence that gas3 is involved in regulating
growth arrest. Alternatively, however, since PMP-22 mRNA
(and to a lesser extent, protein) expression is correlated with
the differentiation of Schwann cells, it remains possible that
PMP-22 RNA negatively regulates cell division in Schwann
cells as well as in other cell types. To accomodate the latter
hypothesis, we would speculate that the lack of correlation of
PMP-22 mRNA expression with the second wave of Schwann
cell division during nerve regeneration is because ofdilution
of the relatively small number of Schwann cells in contact
with the advancing tips of regenerating axons as compared
with the whole nerve sample. Although we do not have direct
evidence to support the idea that PMP-22 serves as both a
myelin protein and as a regulator of cell growth, it should
be pointed out that oligodendrocytes from mutant mice de-
ficient in PLP (jimpy) proliferate more rapidly than normal
(Skoff, 1982), but most of these cells ultimately die (Knapp
et al ., 1986). The existence of these mutations suggests that
PLP may play a more fundamental role in oligodendrocyte
biology than functioning as a myelin structural protein.
Likewise, the possibility remains that PMP-22 may also sub-
serve a similar dual function.
In conclusion, these studies indicate that the PMP-22 pro-
tein is synthesized by Schwann cells and is a major compo-
nent of PNS, but not CNS myelin. Like other myelin pro-
teins, PMP-22 mRNA and protein expression is actively
regulated and correlates with myelin production during
periods of myelination and Wallerian degeneration. Exami-
nation of the predicted structure of the PMP-22 protein re-
veals similarities to the predicted structure of PLP The fact
that both proteins have multiple membrane-spanning do-
mains suggests that these proteins project into both the major
dense line and the intraperiod line of myelin where they may
serve similar functions. Whether PMP-22 or PLP are in-
volved in the regulation ofthe cell cycle awaits further inves-
tigations.
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